For ALK, 2008 was a good year with breakthrough research results and
satisfactory financial results. ALK met its financial forecast and generated a
five-fold increase of the underlying operating profit before contributions from
the company's US-based partner, Schering-Plough. Profit before tax was DKK 157
million. For 2009, ALK expects a continued double-digit growth in the company's
core business, sales of allergy vaccines, and a significant increase in the
company's operating profit.
The full report is attached to this announcement.
ALK invites investors and analysts to a meeting with Management tomorrow at
9.00 a.m. (CET) at the company headquarters 6-8, Bøge Allé, Hørsholm, Denmark.
The meeting will be held in English and webcast live on www.alk-abello.com. It
will be possible to call in with questions.
Danish participants must call in on telephone +45 70 26 50 40 before 8.55 a.m.
(CET), and international participants must call in on telephone +44 208 817
9301 before 8.55 a.m. (CET).
ALK-Abelló A/S
Jens Bager
President and CEO
For further information please contact:
Jens Bager, President and CEO, tel. +45 45 74 75 76
Investor Relations: Per Plotnikof, tel +45 45 74 75 27, mobile +45 22 61 25 25
Press: Jacob Frische, tel +45 45 74 75 51, mobile +45 22 24 75 51
